NeuBase

NeuBase Therapeutics, Inc. Utilizes Proprietary Peptide Nucleic Acid (PNA) Antisense Oligonucleotide (PATrOL)™ Platform to Rapidly Develop Targeted Drugs Capable of Addressing Rare Genetic Diseases Caused by Mutant Proteins in a Single, Cohesive Manner. NeuBase has Advanced Gene Silencing Therapy by Combining the Advantages of Synthetic Approaches with the Precision of Antisense Technology.